Voenno-medicinskij žurnalVoenno-medicinskij žurnal0026-9050Eco-Vector8244010.17816/RMMJ82440Research ArticleA case of tolerance to neprilysin inhibitors as a new factor in the cumulation of mortality in patients with chronic heart failureTsygvintsevA. Atsygvintsev1985@gmail.comLishchukA. N-StorozhilovV. A-the 3rd A.A.Vishnevsky Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation150920203419676905102021Copyright © 2020, Eco-Vector2020Based on four years of clinical experience with saсubitrile/valsartan use, the authors faced the problem of cumulation of mortality in patients. Long-term clinical observation of a comorbid patient who received adequate therapy of high functional class chronic heart failure, which ended in death, is presented. The concept of management of such patients used by us from the perspective of evidence-based medicine is considered.heart failureneprilysin inhibitorssodium uretic peptidesacubitrile/valsartanranolazineсердечная недостаточностьнатрийуретический пептидсакубитрил/валсартанранолазин[Европейское руководство по неотложной кардиологии / Под ред. М.Тубаро, П.Вранкс. - М.: ГЭОТАР-Медиа, 2017. - 960 с.][Руководство по кардиологии в четырех томах. Т. 4: Заболевания сердечно - сосудистой системы / Под ред. Е.И.Чазова. - М.: Практика, 2014. - 976 с.][Chang H.Y., Feng A.N., Fong M.C. et al. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation // J. Cardiol. - 2019. - Vol. 74, N 4. - P. 372-380.][Jhund P., Claggett B., Packer M. et al. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial // Eur. J. Heart Fail. - 2014. - Vol. 16, N 6. - P. 671-677.]